[eDisclosure Notice] SK Bioscience Applies for Phase 3 Clinical Trial Plan of COVID-19 Vaccine in Colombia (Afternoon Summary)
[Asia Economy Reporter Minji Lee] SK Bioscience announced on the 29th that it has applied for the Phase 3 clinical trial plan for the double booster shot of the COVID-19 vaccine GBP510 in Colombia.
▲ Geumbi = Announced the decision to dispose of treasury shares worth 532.66 million KRW. This is to expand liquidity through the disposal.
▲ SK Innovation = Announced that its subsidiary BlueOval SK, LLC has decided on a rights offering worth 501.5 billion KRW to raise facility funds.
▲ Hans Biomed = Announced that a shareholders' meeting will be held at the headquarters on the 28th of next month.
▲ Patron = Announced the decision to lend 36.9 billion KRW to its subsidiary Patron VINA. The loan period is until November 30, 2025, and the loan amount corresponds to 7.7% of the total equity capital.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
▲ Geosoft = Announced that it has changed its business location to 50 Jongno 1-gil, Jongno-gu, Seoul to improve the management environment and work efficiency.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.